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Allogeneic hematopoietic stem cell transplantation is
the only curative option for high risk adult acute
lymphoblastic leukemia (adALL). In the absence of an HLA
identical sibling donor, HLA matched unrelated donor or
HLA mismatched cord blood are alternative stem cell
sources. However, very few data on the outcomes after
umbilical cord blood transplantation (UCBT) for adALL
using myeloablative (MAC) or reduced intensity (RIC)
conditioning regimens have been reported. We conducted
a retrospective survey on the outcomes after UCBT for
adALL and a more speciﬁc analysis for patients with
cytogenetic data transplanted in remission with either
MAC or RIC. From 1996 to 2011, 433 adult patients (pts)
received a UCBT for ALL. Overall 2-year LFS was 37% for
pts in ﬁrst complete remission (CR1, n¼199), 32% for CR2
(n¼138) and 9% for advanced disease (n¼96). Complete
cytogenetic data at diagnosis was available for 316 pts, of
whom 251 were transplanted in CR1 (63%, n¼157) or CR2
(37%, n¼94). Median age at UCBT was 33 years (18 to 66)
and 76% of the pts (n¼191) had an abnormal karyotype at
diagnosis. Pts were analyzed according to the presence of
t(9;22) as Phþ (n¼115) and Ph- (n¼136). Double CBT was
performed in 109 pts (43%) and the median total nucle-
ated cell dose at freezing was 4.02x107/kg. Most pts
received CBU with 1 (n¼74) or 2 (n¼136) HLA disparities.
MAC was given to 177 pts (70%) and 73 (30%) received
RIC. Overall 2-year leukemia- free survival (LFS) was
363%; 37% for Ph- and 35% for Phþ pts (p¼NS). On
multivariate analysis, 3 factors were associated with
improved LFS: age <44 years (HR: 0.6, p¼0.004), CR1 at
transplant (HR: 0.6, p¼0.005) and use of RIC (HR: 0.6,
p¼0.015).
In pts transplanted with MAC (n¼177), most used
regimens were Cy-TBI (27%) and BuþFluþThio (25%).
Median follow-up (FU) was 26 and 35 months for CR1
(n¼107) and CR2 (n¼70). Cumulative incidence (CI) of 60-
day neutrophil recovery was 87% (CR1) and 83% (CR2);
acute GVHD was 43% and 37%, respectively. Two-year CI of
NRM was 41% and 49%; 2-year RI was 24% and 22% for
CR1 and CR2, respectively. Two-year LFS was 35% for CR1
and 30% for CR2. No factor was found to be associated
with LFS, relapse or NRM.In pts transplanted with RIC (n¼73), CyþFluþTBI was
used in 74% (n¼54). Median FU was 31 and 34 months and
median age was 50 and 39 years for CR1 (n¼49) and CR2
(n¼24), respectively. At 2 years, CI of NRMwas 22% (CR1) and
17% (CR2). Two-year RI was 30% and 47%, respectively. Two-
year LFS was 49% (CR1) and 36% (CR2). For pts in CR1,
univariate analysis showed that younger age (< 50 years)
was associated with improved LFS (62% x 36%, p¼0.042) and
lower NRM.
UCBT is an option to treat high risk adALL. MAC was
associated with a LFS comparable with that reported with
other stem cell sources, but strategies to reduce toxicity are
still needed. Results with RIC are encouraging and may be
considered in younger pts. Importantly, in this large series
outcomes after UCBT were similar for Phþ and Ph- ALL.34
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Unrelated cord blood (UCB) is an alternative source of
allogeneic hematopoietic stem cell transplantation (HSCT)
for adults with acute leukemia lacking a HLA matched donor.
Double cord blood unit (dUCBT) has been increasingly used
over single CB unit (sUCBT) after reduced intensity condi-
tioning regimen (RIC). We analyzed 360 adults with ALL (n¼
77) or AML (n¼238) in CR1 (n¼212) and CR2 (n¼148)
transplanted with a sUCBT (n¼131) or a dUCBT (n¼229) after
RIC. Only patients (pts) transplanted with a sUCBT with
a minimum of 2.5x107/kg total nucleated cells (TNC) were
included. Pts were transplanted from 2005-2011 in EBMT
centers. Comparing the recipients of sUCBT and dUCBT in
CR1, there were no statistical differences according to age,
diagnosis (AML or ALL), weight, CMV serostatus, cytogenetic
risk, number of HLA incompatibilities. However, dUCBT were
performed more recently (2009 vs 2008), the time from CR1
to transplant was longer (142 days vs 121 days), more
frequently transplanted with CYþFLUþTBI2Gy (87% vs 68%),
lower frequency of ATG use (21% vs 35%) and they received
higher number of TNC collected (5x107/kg vs 3.9x107/kg) or
infused (4x107/kg vs 3.1x107/kg). Median follow-up was 23
months in both groups.
Cumulative incidence (CI) of 60 days neutrophil recovery
was 82% for dUCBT and 76% for sUCBT (p¼0.86); frequency of
full donor chimerism at day 100 was not statistically
different between dUCBT (81%) and sUCBT (86%). At day 100,
CI of acute GVHD (grade II-IV) was 35% in both groups,
however there was a trend of increased incidence of grade
